Acumen Pharmaceuticals(ABOS) - 2025 Q4 - Annual Results

Financial Performance - Acumen reported a net loss of $121.3 million for the year ended December 31, 2025, compared to a net loss of $102.3 million for the previous year, reflecting an increase of 18.5%[13] - Net loss for 2025 was $121.335 million, compared to a net loss of $102.329 million in 2024, reflecting a 18.6% increase in losses[23] - Net loss per common share, basic and diluted, was $2.00 in 2025, compared to $1.71 in 2024, indicating a 17.0% increase in loss per share[23] Research and Development - Research and Development (R&D) expenses increased to $104.9 million in 2025 from $93.8 million in 2024, primarily due to higher manufacturing and personnel-related costs[8] - Research and development expenses rose to $104.885 million in 2025, up from $93.798 million in 2024, a growth of 11.7%[23] - The company is targeting an Investigational New Drug (IND) filing for its lead clinical candidate in the EBD program by mid-2027[5] - The company expects to report topline results for the Phase 2 ALTITUDE-AD study of sabirnetug in late 2026, which will provide insights into the role of AβOs in Alzheimer's disease[5] - The first patient was dosed in the open-label extension of the ALTITUDE-AD trial in November 2025, allowing participants to receive sabirnetug for up to 52 weeks[8] - The company has enrolled 542 individuals in the ALTITUDE-AD trial, which is designed to evaluate the efficacy and safety of sabirnetug in early Alzheimer's disease patients[12] Cash and Assets - As of December 31, 2025, cash, cash equivalents, and marketable securities totaled $116.9 million, down from $136.1 million as of September 30, 2025, expected to support operations into early 2027[5] - Cash and cash equivalents at the end of the period increased to $54.220 million in 2025 from $35.859 million in 2024, a rise of 51.1%[25] - Acumen's total assets as of December 31, 2025, were $122.8 million, a decrease from $239.0 million in 2024[21] Operating Expenses - Total operating expenses increased to $123.832 million in 2025 from $114.017 million in 2024, representing an increase of 8.0%[23] - General and Administrative (G&A) expenses decreased to $18.9 million in 2025 from $20.2 million in 2024, attributed to reductions in recruiting and consulting costs[13] - Net cash used in operating activities was $115.538 million in 2025, compared to $86.215 million in 2024, an increase of 34.0%[25] Other Income and Securities - Total other income decreased significantly to $2.497 million in 2025 from $11.688 million in 2024, a decline of 78.6%[23] - Purchases of marketable securities were $38.056 million in 2025, down from $170.731 million in 2024, a decrease of 77.7%[25] - Proceeds from maturities and sales of marketable securities were $172.077 million in 2025, compared to $218.774 million in 2024, a decrease of 21.4%[25] Share Information - Weighted-average shares outstanding increased to 60,561,836 in 2025 from 60,013,277 in 2024, an increase of 0.9%[23] - Acumen announced a $35.75 million private placement in March 2026 to advance its AβO-selective Enhanced Brain Delivery (EBD) portfolio, following strong preclinical data[6]